Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the third.
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
<iframe src=https://www.youtube.com/embed/XRlhyHSAEaA></iframe>Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary. | June 5, 2023
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.